Signaling pathways targeted by Wnt-C59, ruxolitinib, ibrutinib, or belumosudil are enriched in both human and murine sclGVHD. (A-B) RNA-seq data were analyzed from 6 patients with sclGVHD and 6 healthy controls (A) as well as from 4 allogeneic (sclGVHD model, vehicle-treated) and 4 syngeneic mice (B). Bubble plots illustrating selected significantly enriched biological processes from Gene Ontology (GO) pathway analysis. The color of each bubble represents the adjusted P value (Padj), whereas the size of the bubble represents the number of differentially expressed genes associated with the respective GO processes. On the left side are marked the signaling pathways directly targeted by Wnt-C59, ruxolitinib, ibrutinib, or belumosudil (WNT–Wnt-C59, BTK–ibrutinib, ROCK–belumosudil, and JAK–ruxolitinib), corresponding to the respective GO processes on the right side. APC, antigen-presenting cell; GTP, guanosine triphosphate.